News Releases

Jasper Therapeutics Announces Proposed Public Offering of Common Stock

January 24, 2023
REDWOOD CITY, Calif. , Jan. 24, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk

Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, Including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare Diseases

January 10, 2023
REDWOOD CITY, Calif. , Jan. 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a biotechnology company developing novel antibody therapies and stem cell transplant conditioning agents targeting c-Kit, today announced, as part of an overall portfolio
Displaying 31 - 39 of 39
Top

External Link

You are now leaving the Jasper Therapeutics, Inc. site to a 3rd party website. Jasper Therapeutics is not responsible for 3rd party website content.